Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues
Author:
Affiliation:
1. Pfizer Inc, CA USA
2. Pfizer Inc, CT USA
Publisher
Japanese Society of Toxicology
Subject
Toxicology
Link
https://www.jstage.jst.go.jp/article/jts/43/1/43_1/_pdf
Reference68 articles.
1. Abdiche, Y.N., Malashock, D.S. and Pons, J. (2008): Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci., 17, 1326-1335.
2. Balanescu, A.R., Feist, E., Wolfram, G., Davignon, I., Smith, M.D., Brown, M.T. and West, C.R. (2014): Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann. Rheum. Dis., 73, 1665-1672.
3. Belanger, P., Butler, P., Butt, M., Bhatt, S., Foote, S., Shelton, D., Evans, M., Arends, R., Hurst, S., Okerberg, C., Cummings, T., Potter, D., Steidl-Nichols, J. and Zorbas, M. (2017): Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment. Toxicol. Sci., 158, 319-333.
4. Bennett, D.L., Koltzenburg, M., Priestley, J.V., Shelton, D.L. and McMahon, S.B. (1998): Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur. J. Neurosci., 10, 1282-1291.
5. Bjerre, B., Wiklund, L. and Edwards, D.C. (1975): A study of the de- and regenerative changes in the sympathetic nervous system of the adult mouse after treatment with the antiserum to nerve growth factor. Brain Res., 92, 257-278.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Out of the dark: the emerging roles of lncRNAs in pain;Trends in Genetics;2024-08
2. Research Progress of Neural Invasion in Pancreatic Cancer;Current Cancer Drug Targets;2024-04
3. Role of imaging for eligibility and safety of a-NGF clinical trials;Therapeutic Advances in Musculoskeletal Disease;2023-01
4. Inter-reader consistency and exclusionary findings during radiographic screening for Phase 3 trials of tanezumab in patients with osteoarthritis;Osteoarthritis Imaging;2022-09
5. Molecular factors governing perineural invasion in malignancy;Surgical Oncology;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3